Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Early dyskinesia--vulnerability.

J O Cole1, G Gardos, L A Boling

  • 1McLean Hospital, Belmont, MA 02178.

Psychopharmacology
|January 1, 1992
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Variation in social feeding behavior and interactions among <i>Caenorhabditis</i> nematodes.

bioRxiv : the preprint server for biology·2025
Same author

Hydration-state-responsive proteins link cold and drought stress in spinach.

Planta·2013
Same author

Long-term treatment of panic disorder with agoraphobia in private practice.

Journal of psychiatric practice·2005
Same author

Anti-interleukin-6 antibodies attenuate inflammation in a rat meningitis model.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine·2001
Same author

Clozapine in the treatment of refractory psychotic mania.

The American journal of psychiatry·2000
Same author

Diurnal regulation of Hsp70s in leaf tissue.

The Plant journal : for cell and molecular biology·2000

Unipolar and bipolar patients showed higher vulnerability to drug-induced dyskinesia. While lithium did not delay onset, antiparkinson drugs and electroconvulsive therapy may reduce dyskinesia risk.

Area of Science:

  • Psychiatry
  • Neuroscience
  • Pharmacology

Background:

  • Antipsychotic medications are crucial for treating psychiatric disorders but can cause movement disorders like tardive dyskinesia.
  • Understanding patient vulnerability factors is essential for risk mitigation and treatment personalization.

Purpose of the Study:

  • To investigate the relative vulnerability of psychiatric patients to developing dyskinesia.
  • To examine the influence of specific drug exposures (antipsychotics, antiparkinson drugs, lithium) and electroconvulsive therapy on dyskinesia onset.

Main Methods:

  • A cohort of 100 psychiatric patients with recent onset dyskinesia was analyzed.
  • Exposure history to antipsychotics, antiparkinson drugs, lithium, and electroconvulsive therapy was recorded.
  • Diagnostic groups were compared for relative vulnerability.

Related Experiment Videos

Main Results:

  • Unipolar and bipolar patients exhibited greater vulnerability to dyskinesia compared to other diagnostic groups.
  • Lithium exposure did not demonstrate a delaying effect on dyskinesia development.
  • Extended exposure to antiparkinson drugs correlated with a delayed onset of dyskinesia.
  • Prior electroconvulsive therapy exposure was linked to reduced vulnerability to dyskinesia.

Conclusions:

  • Diagnostic subtype (unipolar/bipolar) significantly influences dyskinesia risk.
  • Antiparkinsonian medications and electroconvulsive therapy may play protective roles against antipsychotic-induced dyskinesia.
  • Further research is warranted to elucidate the mechanisms behind these observed protective effects.